Not Just What, But When: Neoadjuvant Pembrolizumab in Melano

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Related Keywords

New York , United States , Paris , France General , France , United Kingdom , Fox Chase Cancer Center , Pennsylvania , Texas , Philadelphia , London , City Of , Anthonyj Olszanski , Sapna Patel , James Larkin , Maya Dimitrova , Development Agreement , University Of Texas Md Anderson Cancer Center , European Society For Medical Oncology , Langone Perlmutter Cancer Center , Cancer Center , European Society , Medical Oncology , Perlmutter Cancer Center , Medscape Medical News , New Results , Royal Marsden Hospital , Vice Chair , Cooperative Research , Melanoma , Malignant Melanoma , Skin Cancer , Alignant Skin Neoplasm , Surgery , Neoadjuvant , Neoplasm , Tumor , Biologic Therapy , Immunotherapy , Clinical Research , Clinical Trials , Linical Studies , Oncological Medicine , United Kingdom Site Content ,